Aclarion at Lytham Partners fall investor conference: growth and proof

On Tuesday, 29 September 2026, Aclarion, Inc. (ACON) used the Lytham Partners Fall 2026 Investor Conference to present a growth story driven by clinical data, early commercial success, and a vast market opportunity. CEO Brent Ness outlined that Aclarion's NOCISCAN platform could enhance treatment decisions for chronic low back pain while acknowledging that payer coverage, physician usage, and additional trial outcomes still play a role in broader adoption.

Aclarion described NOCISCAN as an AI-powered tool that leverages MR spectroscopy to uncover biomarkers associated with spinal pain, transforming intricate imaging data into a straightforward physician report. With a focus on addressing a $32 billion market across chronic low back pain, Aclarion highlighted a remarkable 97% surgical success rate when NOCISCAN-positive discs were treated, compared to a mere 54% when left untreated.

The company reported $16 million in cash as of June 30, 2026, with ample runway extending into 2027 and no debt. Ness emphasized that Aclarion is targeting one of the largest healthcare expense categories: chronic low back pain. He described NOCISCAN as an innovative platform that utilizes MR spectroscopy to detect pain-related biomarkers in the spine, simplifying complex imaging data into an accessible physician report.

Around 266 million individuals worldwide suffer from chronic low back pain, and approximately 22 million lumbar MRIs without contrast are conducted annually globally. Aclarion emphasized that its immediate goal is the U.S. and the U.K., where it anticipates a combined $16.5 billion revenue potential upon full market penetration across various treatment pathways.

The company projected that NOCISCAN could yield $9.8 billion if applied to every lumbar MRI in the U.S. and U.K., $6.7 billion if utilized with every pain management injection in the U.S., and $478 million if integrated into each spinal fusion or disc replacement surgery in the U.S. The current standard of care, including spinal fusion and disc replacement procedures, remains costly and imperfect, with success rates ranging from 48% to 54%.

Aclarion also noted that about 6% of these procedures lead to revision surgery, resulting in over $1 billion in annual costs within the U.S. alone. During the presentation, Aclarion heavily emphasized clinical results supporting NOCISCAN as a non-invasive alternative to discography, the prevailing diagnostic standard. Ness highlighted the product's objectivity, painlessness, radiation-free nature, and cost-effectiveness, being approximately 50% cheaper than discography.

NOCISCAN measures acid pain biomarkers and structural integrity biomarkers using MR spectroscopy, generating straightforward reports for physicians. The technology offers an MRI-like patient experience without the invasive procedure. The Gornet Trial, published in 2019 in the European Spine Journal, served as a key proof point, enrolling 139 patients, with 97% improvement among those treated when all NOCISCAN-positive discs were addressed, compared to 54% improvement when left untreated.

Despite early commercial momentum, with a 141% increase in NOCISCAN volume in the first half of 2026 compared to the same period in 2025, Aclarion's presentation focused on its continued clinical success and expanding commercial reach. The company reported private payer approvals in England, including three of the four largest insurers—AXA, Aviva, and Vitality—plus reimbursement at The London Clinic.

Aclarion plans to extend coverage to Bupa and other private insurers and broaden its use to additional care sites across the U.K. CEO Brent Ness expressed confidence in the company's financial position, stating that Aclarion had $16 million in cash as of June 30, 2026, with a runway lasting well into 2027 and no debt or preferred shares outstanding.

The company is using its resources to propel the CLARITY Trial, led by Dr. Nicholas Theodore of the University of Arizona College of Medicine – Phoenix, a national randomized controlled study enrolling 300 patients across 11 sites. The trial, expected to commence in 2025, will measure outcomes at 3, 6, 12, and 24 months, with the primary endpoint at 12 months.

The study aims to bolster the evidence base for payers and physicians, particularly by comparing blinded and unblinded groups and assessing outcomes for missed versus matched treated levels. Analysts have set a price target of $7.50 for Aclarion shares, suggesting almost 200% upside from current levels. While Aclarion remains unprofitable with a negative earnings per share of $6.22, the company's growth trajectory appears promising.